On November 13, 2017 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, reported that the Company’s management will participate in two upcoming investor conferences. These two conferences include (Press release, MacroGenics, NOV 13, 2017, View Source [SID1234522005]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2017 Healthcare Conference in New York, NY. MacroGenics’ presentation is scheduled to take place on Tuesday, November 14, 2017 at 9:30 am ET.
Citi 2017 Global Healthcare Conference in New York, NY. MacroGenics’ management will participate in one-on-one meetings with investors on Thursday, December 7, 2017.

A webcast of the Stifel conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.